FMS Stock Recent News

Fresenius Medical Care has shown some improvement in recent trends, but still faces headwinds and pressures in its markets. Analysts have consistently underestimated FMS's performance, and I think the company has a potential upside of 15% annually or 44% until 2025E. However, the native Fresenius ticker may be a better investment due to its diversification and better fundamentals, depending on your goals.

Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q4 2022 Earnings Conference Call February 22, 2023 9:30 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chair & Chief Executive Officer Conference Call Participants Graham Doyle - UBS Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF Christoph Gretler - CS Ed Ridley-Day - Redburn Lisa Clive - Bernstein James Vane-Tempest - Jefferies Victoria Lambert - Berenberg Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. I am Nicolas, your Chorus Call operator.

I've been unfailingly bullish in the long-term on Fresenius - both the medical care, but also the main company headquartered in Germany. Fresenius has had an extremely tricky set of years, due to company challenges and what could be characterized as mismanagement (without being wrong).

Dividend growth blue-chips are the best performing assets in history. There are no more dependable dividend growth blue-chips for the 2023 recession than dividends aristocrats.

Three underpriced healthcare stocks provide an opportunity.

Profit estimates are moving in the wrong direction.

Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q3 2022 Earnings Conference Call October 31, 2022 10:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Carla Kriwet - Chief Executive Officer & Chair of the Management Board Helen Giza - Deputy Chief Executive Officer, Chief Financial Officer & Chief Transformation Officer Conference Call Participants Tom Jones - Berenberg Graham Doyle - UBS James Vane-Tempest - Jefferies Hassan Al-Wakeel - Barclays Veronika Dubajova - Citi Oliver Metzger - ODDO BHF David Adlington - JPMorgan Robert Davies - Morgan Stanley Falko Friedrichs - Deutsche Bank Szegi Oezener - HSBC Operator Ladies and gentlemen, thank you for standing by. I'm Nathalie your Chorus Call operator.

Kidney dialysis provider Fresenius Medical Care (FMC) on Sunday revised down its forecast for 2022, expecting net income to decline this year, dragged down by rising labour costs and a slower than expected recovery in North America business.